Critically, in patients with diabetes and the associated increased cardiovascular risk, metformin combined with SGLT2i (empagliflozin) as well as specific GLP-1 receptor agonists (semaglutide and liraglutide) reduced all-cause mortality and cardiovascular death (187). The gene discussed is GLP1R; the disease is diabetes mellitus.